Onconova Therapeutics Inc
NASDAQ:TRAW
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Zorlu Enerji Elektrik Uretim AS
IST:ZOREN.E
|
TR |
|
Namura Shipbuilding Co Ltd
TSE:7014
|
JP |
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
|
Onconova Therapeutics Inc
NASDAQ:TRAW
|
13.1m USD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
883.9B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
585.2B USD |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
237.5B GBP |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
299.1B USD |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
236.4B CHF |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
161B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
120B USD |
Loading...
|
Market Distribution
| Min | -4 087 900% |
| 30th Percentile | -5.1% |
| Median | 6% |
| 70th Percentile | 14.8% |
| Max | 1 032 600% |
Other Profitability Ratios
Onconova Therapeutics Inc
Glance View
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. The company is headquartered in Newtown, Pennsylvania and currently employs 14 full-time employees. The company went IPO on 2013-07-25. The company has molecularly targeted agents designed to disrupt specific cellular pathways for cancer cell proliferation. The company has the two clinical-stage programs: narazaciclib (ON 123300), which is a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and rigosertib administered alone or in combination for the treatment of solid tumors. Narazaciclib is a multi-targeted kinase inhibitor targeting cyclin-dependent kinases (CDK) 2, 4, 6, and 9, AMPK related protein kinase 5 (ARK5), and colony-stimulating factor 1 receptor (CSF1R). The company is supporting investigator-initiated studies (ISS) that are exploring the use of rigosertib for cancers driven by mutated Ras genes, including a Phase 1/2a study of rigosertib in combination with a PD-1 inhibitor.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Onconova Therapeutics Inc is -554.7%, which is above its 3-year median of -14 766.3%.
Over the last 2 years, Onconova Therapeutics Inc’s Operating Margin has increased from -8 572.1% to -554.7%. During this period, it reached a low of -62 717.2% on Mar 31, 2025 and a high of -554.7% on Oct 30, 2025.
